Literature DB >> 28567596

Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies.

Ashish Sharma1, Benjamin Weber2, Bernd Meibohm3.   

Abstract

Year:  2017        PMID： 28567596     DOI： 10.1007/s40261-017-0534-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  4 in total

1.  Essential criteria for pharmacokinetic studies supporting bioequivalence of inhaled tiotropium bromide products.

Authors:  Ashish Sharma; Benjamin Weber; Martina Wein; Christoph Hallmann; Bernd Meibohm
Journal:  Clin Pharmacol Drug Dev       Date:  2015-06-02

2.  Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.

Authors:  Donald P Tashkin; Eric D Bateman; Paul Jones; Valentina B Zubek; Norbert Metzdorf; Dacheng Liu; Thomas Leonard; Emmanuelle Clerisme-Beaty; Robert A Wise
Journal:  Respir Med       Date:  2016-10-11       Impact factor: 3.415

Review 3.  Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients.

Authors:  David Price; Ashish Sharma; Frank Cerasoli
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

4.  Pharmacokinetic Bioequivalence of Two Inhaled Tiotropium Bromide Formulations in Healthy Volunteers.

Authors:  Jaime Algorta; Laura Andrade; Marta Medina; Valentin Kirkov; Sacha Arsova; Fumin Li; Jingduan Chi
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859
  4 in total
  2 in total

1.  Response to Sharma et al.: Long Pulmonary Residence Time and Plasma Half-Life of Tiotropium: Implications for Pharmacokinetic Bioequivalence Studies.

Authors:  Jaime Algorta
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  Efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI in the treatment of stable COPD.

Authors:  Xiao Ma; Jingjing Xu; Jun Yang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.